Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.50 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2516674 | 0.98 | HRH3 (0.49) | HRH3L3MBTL3L3MBTL1KEAP1SMN1; SMN2 | |
| SCHEMBL19495063 | 0.94 | HRH3 (0.49) | HRH3L3MBTL3L3MBTL1KDM1ACYP3A4 | |
| SCHEMBL1309460 | 0.88 | ALOX15 (0.48) | HRH3L3MBTL3L3MBTL1KDM1A | |
| SCHEMBL1309249 | 0.86 | ALOX15 (0.50) | HRH3L3MBTL3L3MBTL1KDM1A | |
| SCHEMBL7471957 | 0.85 | SIGMAR1 (0.51) | — | |
| SCHEMBL3979601 | 0.82 | SIGMAR1 (0.49) | KEAP1SMN1; SMN2 | |
| SCHEMBL7513389 | 0.82 | KEAP1 (0.48) | KEAP1SMN1; SMN2KDM1A | |
| SCHEMBL24326956 | 0.81 | HRH3 (0.50) | HRH3L3MBTL3L3MBTL1SMN1; SMN2KDM1A | |
| SCHEMBL24218139 | 0.79 | GNAO1 (0.53) | HRH3L3MBTL3L3MBTL1SMN1; SMN2 | |
| SCHEMBL13091289 | 0.79 | KEAP1 (0.42) | HRH3KEAP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131890-B1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | PASTEUR INSTITUT KOREA (KR) | 2019-04-24 | — | — | EP | disclosed |
| EP-3131890-B1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | PASTEUR INSTITUT KOREA (KR) | 2019-04-24 | — | — | EP | disclosed |
| US-9809602-B2 | Compounds for treating viral infections | INSTITUT PASTEUR KOREA (KR) | 2017-11-07 | — | — | US | disclosed |
| US-9809602-B2 | Compounds for treating viral infections | INSTITUT PASTEUR KOREA (KR) | 2017-11-07 | — | — | US | disclosed |
| US-9809602-B2 | Compounds for treating viral infections | INSTITUT PASTEUR KOREA (KR) | 2017-11-07 | — | — | US | disclosed |
| EP-2188299-B1 | COMPOUNDS FOR TREATING DIABETES | OHR PHARMACEUTICAL INC (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-3131890-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | Institut Pasteur Korea (KR) | 2017-02-22 | — | — | EP | disclosed |
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | INSTITUT PASTEUR KOREA (KR) | 2017-02-16 | — | — | US | disclosed |
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | INSTITUT PASTEUR KOREA (KR) | 2017-02-16 | — | — | US | disclosed |
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | INSTITUT PASTEUR KOREA (KR) | 2017-02-16 | — | — | US | disclosed |
| WO-2015158908-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | INSTITUT PASTEUR KOREA (KR) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015158908-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | INSTITUT PASTEUR KOREA (KR) | 2015-10-22 | — | — | WO | disclosed |
| WO-2007117180-A1 | AZAHETEROCYCLES, COMBINATORY LIBRARY, FOCUSED LIBRARY, PHARMACEUTICAL COMPOSITION AND METHODS FOR THE PRODUCTION THEREOF | 'CHEMICAL DIVERSITY RESEARCH INSTITUTE' LTD. (RU) | 2007-10-18 | — | — | WO | disclosed |
| WO-2002099388-A2 | BENZODIAZEPINE BRADYKININ ANTAGONISTS | MERCK & CO., INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, EIF2AK2 | HRH3 2108/4885L3MBTL3 842/4885L3MBTL1 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.